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Summary Background: IL-2 and the IL-2 receptor are most commonly connected to
lymphocytes and the proliferation of T-cells. In addition, the co-stimulatory
molecules CD28, CD86 and CD40 are associated to lymphocytes and antigen
processing. Under certain conditions, eosinophils are also able to express these
antigens on their surface. Objective: In this study we explored the apoptotic
mechanisms by looking for a surface expression on eosinophils exclusive to apoptosis.
Methods: Flow cytometry analysis was performed on fresh and cultured isolated
eosinophils from healthy blood donors and allergic patients. The cells were cultured
up to 72 h and then incubated with monoclonal antibodies toward cell surface
antigens. Results: After culture, the apoptotic eosinophils, but not the viable cells,
expressed CD25, CD122, CD28 (B7-ligand) and CD86 (B7-2). The expression of CD9, a
common eosinophil marker, was maintained on viable cells, but absent on the
apoptotic eosinophils. Addition of IL-2 to the culture did not influence the viability of
the cells. Conclusion: Our data suggest that apoptotic eosinophils have a unique
signalling system and might function in ways different from the role of the living
eosinophil. The apoptotic eosinophil expresses markers that indicate communication
with lymphocytes and antigen-presenting cells.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
A few studies have suggested that eosinophils are
able to act as antigen-presenting cells (APC)1,2 and
that they not only express receptors for antigen
binding or cell activation (e.g., Fc receptors and
b1and b2 integrins) but also receptors more
commonly observed on other cell types, including
T- and B-lymphocytes. The interleukin-2 (IL-2)
receptor a-chain (CD25) has been demonstrated
on eosinophils from patients suffering from hyper-
eosinophilia of varying causes.3–7 IL-2 is an im-
portant proliferatory cytokine, mostly connected
to lymphocytes where it is crucial for the prolifera-
tion and maturation of T-, B-cells and macro-
phages.8 Recently, IL-2 was also shown to inhibit
eosinophil migration, an effect that was counter-
acted by interleukin-5 (IL-5).9
Expression of CD28 and CD86 has been detected
on eosinophils after culture with interleukin-3 (IL-
3), granulocyte–macrophage colony-stimulating
factor (GM-CSF) and IL-5.10,11 CD28 and CD86 are
co-stimulatory receptors involved in antigen pre-
sentation.12,13 CD86 is expressed by activated B-
cells, monocytes and dendritic cells and CD28 by T-
cells.14 Eosinophils have also been shown to express
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CD40 and the CD40 ligand (CD154).15,16 The ligation
of CD40 with its ligand CD154 is known to be a
mediator of lymphocyte communication, as well as
of several other immune and inflammatory re-
sponses, such as prothrombotic activities and
expression of adhesion molecules, cytokines, ma-
trix-degrading enzymes and mediators of apopto-
sis.17 The property of the eosinophil to vary the
expression of cell surface receptors under different
circumstances might be connected to the diverse
suggested roles of the eosinophil, including tissue
repair, fibrosis, tumour defence, defence against
parasites and allergic inflammation.18–23
Apoptosis, programmed cell death, is crucial for
clearance of cells from an inflamed site and is
generally considered an important feature in the
clearance of the inflammatory process of allergic
diseases. Recently, it has been suggested that the
apoptotic process might not merely be non-inflam-
matory, but actively anti-inflammatory by stimula-
tion of the release of certain anti-inflammatory
components in other cells.24 This position adds new
importance to apoptosis.
The aim of the present study was to investigate
the expression of cell surface receptors in relation
to the apoptotic process in eosinophils. The
expression of the IL-2 receptor a- and b-chain
(CD25 and CD122), the co-stimulatory receptors
B7.2 (CD86) and B7-ligand (CD28) and CD40 on fresh
and living and apoptotic eosinophils was examined
by flow cytometry. Isolated eosinophils were
cultured without added cytokines up to 72 h.
Furthermore, the effect of IL-2 on the survival of
the cells was examined by adding IL-2 to the
culture medium.
Materials and methods
Subjects
The individuals participating in the study were both
healthy individuals and allergic patients.
The group of healthy individuals consisted of 10
(three men and seven women) healthy, non-atopic
hospital employees with a mean age of 38 years
(range 27–59 years). They had no allergic symptoms
and a negative skin prick test to birch pollen.
Birch pollen-atopic patients, 21 (11 men and 10
women), with a mean age of 40 years (range 20–72
years) were also included in the study during the
birch pollen season. All patients showed a positive
skin prick test, Solupprick SQ Birch (ALK-Abell !o,
H /orsholm, Denmark) to birch pollen and had
symptoms of rhinoconjunctivitis during the birch
pollen season. None of the patients were smokers
and no one was undergoing specific immunother-
apy. During the pollen season, they were allowed to
use inhaled b2-agonists and antihistamines, but not
inhaled or oral steroid medication.
Study design
The study was performed out of season and during
two birch pollen seasons in the springs of 1998 and
2000. The data, however, were mainly collected
during 2000 but are partially combined with data
from the season of 1998. Both these seasons had
very high birch pollen counts and samples were
collected when the pollen counts had reached high
levels and continuously collected the following
weeks.
The studies were approved by the ethical
committee of the medical faculty of Uppsala
University.
Isolation of eosinophils
The isolation was performed on heparinized blood.
The mononuclear leukocytes were removed by
separation using Percoll gradient centrifugation.25
The erythrocytes were then lysed by ice-cold,
sterile water and cell debris removed by washing.
The granulocytes were counted and incubated with
anti-CD16 MACS particles (Miltenyi Biotec GmbH,
Bergisch Gladbach, Germany) for 1 h.25 These
magnetic beads bind to the CD16 receptors of the
neutrophils, and when added to a column in a
magnetic field, the neutrophils will remain in the
column while the CD16 negative eosinophils are
eluted from the column. After washing and collec-
tion of the eosinophils, the cell suspension con-
tained 99% pure eosinophils.
Culture of the purified eosinophils
After purification, the cells were divided into two
fractions: one that was examined the same day and
one that was cultured in 96-well culture plates for
up to 3 days.
The eosinophils were cultured in a medium
consisting of RPMI-1640 medium (Life Technologies,
Paisley, Scotland), 20% foetal calf serum (FCS) (Life
Technologies), L-glutamine (2mmol/l) (Biochrom
KG, Berlin, Germany), penicillin (100 IU/ml) and
streptomycin (100 mg/ml) (Biochrom KG). Cell
culture was performed in 96-well tissue culture
plates in 5% CO2 at 371C. The recovery of cells from
the tissue culture plates was >98% through the
whole culture period. After culture, the eosinophils
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were aliquoted into tubes to give approximately
50 000 cells in each and were then incubated with
fluorescein-di-acetate (FDA) or fluorescein-isothio-
cyanate (FITC)-labelled monoclonal antibodies
(MoAbs).
Culture in the presence of IL-2
In some experiments the isolated eosinophils were
cultured in the presence of IL-2 (R&D Systems, Inc.,
Minneapolis, MN, USA) at a concentration of
10–11mol/l.9 When the cells were harvested from
culture and before examination in the flow cyt-
ometer, the cytokine was washed away with PBS–
0.5% BSA.
Staining with antibodies to cell surface
receptors and with FDA, propidium iodide
(PI) and Annexin V
The fresh or cultured cells were incubated for
30min on ice with the following FITC-labelled
antibodies: anti-CD25 (Coulter Corporation, Miami,
USA), anti-CD28 (Dakopatts A/S, Glostrup, Den-
mark), anti-CD40 (Pharmingen, Becton-Dickinson),
anti-CD86 (Dakopatts) and anti-CD122 (Coulter
Corporation, Miami, USA). The fresh and cultured
cells were also in separate analyses incubated for
30min on ice with FDA (0.17mg/l) (Sigma-Aldrich,
St Louis, MI, USA), PI (5mg/l) (Orpegen Pharma,
Heidelberg, Germany) or FITC-labelled Annexin V
(PharMingen, San Diego, CA, USA). An irrelevant
control antibody, X927, was used as negative
control (Dakopatts). After incubation, the cells
were washed with PBS–0.5% BSA and analysed by
flow cytometry.
Analysis by flow cytometry
The flow cytometer used was a Coulter EPICS XL-
MCL (Coulter Company Inc., Miami, FL, USA).
Instrument calibration was performed daily accord-
ing to the recommendation of the manufacturer. On
average, 10 000 cells from each sample were
analysed in the flow cytometer.
The FS-SSC histogram pattern was used to divide
the cells into living and apoptotic eosinophils,
according to the principle previously described.26
Apoptotic eosinophils were identified by a lower
forward scatter (FS) and a slightly higher side
scatter (SSC) than the fresh cells, FDA negative,
Annexin V positive and a hypodiploid staining
pattern with PI.26 Gates were set on the popula-
tions and the staining of the cells in the gates and
all cells, respectively, were measured as mean
fluorescence intensity (MFI) of the whole popula-
tion or relative number of positive cells (%). For
each experiment, the background fluorescence was
subtracted, as the auto fluorescence increases on
eosinophils in culture and especially on apoptotic
eosinophils.
Statistics
The results are expressed as median and inter-
quartile ranges or total range. The Mann–Whitney
U-test, Wilcoxon matched pair test and the Spear-
man rank correlation coefficient were used to
analyse the results. The statistical calculations
were done by use of the software Statistica
(StatSoft. Inc., Tulsa, OK, USA).
Results
Viability of cultured eosinophils
The median viability after culture in RPMI with 20%
FCS, of eosinophils from the whole population of
individuals was 27% (range 2–83) at 48 h and
decreased to 8% (0.5–80) after 72 h in culture. This
survival was lower than expected from a previous
publication26 and since the range was very wide the
individuals were divided into different groups
related to the presence of allergic symptoms. After
48 h in culture around 50% of the eosinophils from
the healthy individuals were still viable; after 72 h
in culture, the viability decreased to approximately
25% (Table 1). This finding is consistent with earlier
results using the same conditions.26 Cultured
eosinophils obtained from both healthy individuals
and birch pollen-allergic patients during the birch
pollen season showed a significantly lower viability
(Po0:01) after 48 and 72 h in culture than
eosinophils out of season.
Cell surface expression of the IL-2 receptor
a- and b-chains
Fresh eosinophils showed no significant expression
of CD25. After 48 h in culture, the amount of CD25
expressing cells was significantly up-regulated
among apoptotic eosinophils as compared with
fresh (Po0:01) and viable (Po0:01) cultured
eosinophils (Fig. 1). The relative amount of CD25
expressing viable eosinophils after 48 h in culture
was not altered compared with fresh eosinophils.
When comparing the MFI, the intensity of the CD25
cell surface expression on apoptotic eosinophils
after 48 h in culture was significantly higher than
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that on fresh eosinophils (Table 2). After 72 h in
culture, the level of CD25 expressing apoptotic
eosinophils was still significantly higher than that of
fresh and viable cultured eosinophils (Po0:01), but
unchanged compared with apoptotic eosinophils
after 48 h in culture (Fig. 1 and Table 2).
However, when comparing apoptotic eosinophils
from the two groups of individuals apoptotic
eosinophils from the birch pollen-allergic patients
demonstrated a significantly higher cell surface
expression of CD25 [4.0 (2.0–6.0) versus 1.8 (1.1–
2.8), Po0:05] than apoptotic eosinophils from the
non-allergic group, when measured as MFI after
48 h in culture. This result indicates an increased
number of CD25 molecules per cell on the apoptotic
eosinophils from allergic subjects. The relative
number of apoptotic eosinophils expressing CD25
after 48 h in culture evidenced a negative relation-
ship to the relative number of viable eosinophils
(r ¼ 0:49; Po0:001). Fresh eosinophils did not
show any significant expression of the IL-2 receptor
b-chain (CD122) (Fig. 2). After 48 and 72 h in
culture, about 50% of the apoptotic eosinophils
(Po0:001) expressed CD122 (Fig. 2). When mea-
sured as MFI, the intensity of the expression of
CD122 on apoptotic eosinophils increased as
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Fig. 1 Expression of CD25, the IL-2 receptor a-chain, on living (closed circles) and apoptotic (open circles) eosinophils
during culture, n ¼ 38: Results are presented as median and quartile ranges. Significant differences between the
expression on apoptotic and living eosinophils are represented by ***(Po0:001).
Table 1 Viability of eosinophils in culture. Eosinophils from healthy individuals during and out of the birch pollen
season (baseline) and from birch pollen-allergic patients during season.
Group Sample Viability (%)
0 h fresh cells 48 h culture 72 h culture
Healthy
individuals
Out of season 94.8 58.2 24.8
n ¼ 10 (89.297.9) (37.273.4) 18.040.0)
Healthy
individuals
During season 91.8 18.1** 4.0**
n ¼ 10 (91.2–94.9) (12.6–31.0) (1.9–9.0)
Allergic
patients
During season 94.2 25.3## 6.1#
n ¼ 21 (89.496.8) (19.937.2) (4.312.6)
Results are presented as median and interquartile ranges. Statistical evaluations of the comparison between viability of
eosinophils from healthy individuals during and out of the birch pollen season (**Po0:01) and of eosinophils from healthy
individuals out of season and patients during season (#Po0:05 and ##Po0:01) are indicated.
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compared with fresh eosinophils (Table 3). Viable
cultured eosinophils did not reveal any significant
expression of CD122 (Fig. 2). A relationship
between the relative proportion of apoptotic
eosinophils expressing CD122 and the proportion
of viable eosinophils was noted (r ¼ 0:53; Po0:01
at 48 h and r ¼ 0:36; Po0:05 at 72 h).
Culture of eosinophils in the presence of IL-2
To investigate some of the possible consequences of
the expression of IL-2 receptor a- and b-chain on
apoptotic eosinophils, eosinophils were cultured in
the presence of IL-2. The results indicated that
culture of eosinophils in the presence of IL-2 at a
concentration of 1011mol/l affected neither the
viability of the cells nor the expression of CD25 or
CD122 (Table 3).
Cell surface expression of CD28, CD86 and
CD40
Fresh eosinophils showed no significant expression
of CD28, CD86 or CD40, (Figs. 3–5, Table 2). A
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Table 2 Cell surface expression of eosinophils measured as mean fluorescence intensity (MFI).
Antigen 0 h freshly isolated cells 48 h apoptotic cells 48 h p-value 72 h apoptotic cells 72 h p-value
CD25 0.022 3.01 o0.01 3.72 o0.01
n ¼ 38 (0.0030.05) (2.435.08) (2.735.31)
CD122 0.006 1.52 o0.05 2.12a o0.05
n ¼ 22 (0.0020.012) (0.82.14) (1.603.15)
CD28 0.002 1.55 o0.05 1.54 o0.05
n ¼ 21 (0.0000.005) (1.032.26) (1.412.08)
CD86 0.005 0.53 o0.05 0.824 ns
n ¼ 21 (0.0030.008) (0.4511.65) (0.5790.604)
CD40 0.002 0.108 ns 0.132 ns
n ¼ 27 (0.0000.005) (0.0150.175) (0.0680.19)
Results are presented as median and interquartile ranges and show the expression after subtraction of background fluorescence.
Statistical evaluations of the comparison of the expression after 48 and 72 h with the basal expression on fresh eosinophils are
shown.
aSignificant increase as compared with the expression after 48 h (Po0:05).
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Fig. 2 Expression of CD122, the IL-2 receptor b-chain, on living (closed circles) and apoptotic (open circles) eosinophils
during culture, n ¼ 22: Results are presented as median and quartile ranges. Significant differences between the
expression on apoptotic and living eosinophils are given by *** (Po0:001).
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significant proportion of the apoptotic eosinophils
(Po0:001) showed expression of CD28 and CD86 on
the cell surface after 48 and 72 h in culture, but no
significant expression of CD40 (Figs. 3–5, Table 2).
When measured as MFI, the intensities of the cell
surface expression of CD28 and CD86 on apoptotic
eosinophils were increased as compared with fresh
eosinophils. The intensity of CD28 expression on
apoptotic eosinophils from allergic patients during
the birch pollen season was significantly higher
than that of healthy individuals after 48 h in culture
[2.1 (1.6–2.9) versus 1.03 (0.4–1.4) (Po0:01)]. The
viable cultured eosinophils revealed no expression
of CD28, CD86 or CD40.
The relative amount of apoptotic eosinophils
expressing CD28 and CD86 after 48 h in culture
showed a significant relationship to the proportion
of viable eosinophils from all subjects (for CD28,
r ¼ 0:60; Po0:001 and at 72 h r ¼ 0:41; Po0:05
and for CD86, r ¼ 0:6; Po0:001).
Surface expression of CD9
To investigate whether the up-regulation of surface
markers was a general phenomenon, the expression
of CD9, a commonly used eosinophil marker, was
examined before and after culture. All the fresh
isolated eosinophils expressed CD9 and after 48 h in
culture 92% of the viable cells expressed CD9. After
72 h of culture 70% of the viable cells showed an
expression of CD9. The apoptotic eosinophils,
however, had lost the expression of CD9, showing
only 2% and 1% expression after 48 and 72 h in
culture, respectively.
Discussion
The present study demonstrates that apoptotic
eosinophils express the IL-2 receptor a- and b-
chains and the co-stimulatory molecules CD28 and
CD86, but not the CD40 receptor. This expression is
exclusive to the apoptotic cells and was not altered
by the addition of IL-2 to the culture medium. The
expression was contrasted by the expression of
CD9, which was maintained on viable cells, but
decreased on the apoptotic eosinophils. Further-
more, other surface markers like the b2-integrins,
Fcg-receptors and several activation markers, also
decrease their expression on the apoptotic cells at
the same time as the expression on the living cells
is preserved (to be published).
In contrast to fresh and living eosinophils in
culture, the major part of the apoptotic eosinophils
revealed an expression of CD25 and CD122 (Figs. 1
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and 2). Measured as MFI, the increase was many-
fold compared with living cells, suggesting that not
merely the number of positive cells was increased
but also the amount of receptors expressed per
cell. The addition of IL-2 to the eosinophils in
culture did not have any functional consequences
for the viability of the cells (Table 3), however. The
expression of the IL-2 receptor chain a (CD25) has
been observed on eosinophils from hypereosinophi-
lic patients and patients with eosinophilia caused
by graft versus host disease, eosinophils cultured in
the presence of IL-3 and GM-CSF or patients
receiving IL-2 treatment.3–7,27 The IL-2 receptor
consists of three chains. Whether the a-, b- and g-
chains are all required for signalling in eosinophils
is not known, but at least the a- and b-chains are
required in lymphocytes.8
CD28, also known as the B7 ligand, is usually seen
on T-cells and CD86, or B7-2, is seen on B-cells and
has important functions in the antigen-presenting
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Fig. 4 Expression of CD86, B7-2, on living (closed circles) and apoptotic (open circles) eosinophils during culture,
n ¼ 21: Results are presented as median and quartile ranges. Significant differences between the expression on
apoptotic and living eosinophils are given by *** (Po0:001).
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Fig. 3 Expression of CD28, the B7-ligand, on living (closed circles) and apoptotic (open circles) eosinophils during
culture, n ¼ 21: Results are presented as median and quartile ranges. Significant differences between the expression on
apoptotic and living eosinophils are given by ***(Po0:001).
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process and in building up the immunological
synapse.28,29 The present study demonstrates the
expression of CD28 and CD86 on the apoptotic
eosinophils. The increase of CD86 was slightly lower
than that of CD28. Measured as MFI, the increase of
CD28 was at the same level as the increase of CD25,
although the number of positive cells was slightly
lower. The increase of CD86, as measured as MFI,
was lower than CD28 or CD25, but still substantially
higher than the living cells. An investigation of
eosinophils from patients with pronounced
eosinophilia suffering from hypereosinophilic syn-
drome, skin diseases and allergy demonstrated a
varying expression (up to 60% positive cells) of
CD28 and CD86, but not CD80 (B7-1) on fresh
eosinophils.11 Another study showed that culture
of eosinophils in the presence of IL-3 induced
the expression of CD86.10 Eosinophils stimulated
by IL-3, IL-5 and GM-CSF were shown to present,
but not process, antigens.1,10 Ligation of CD28
led to the production of IL-2 and IFNg from
the eosinophils.11 CD40 is expressed by B-cells,
monocytes and dendritic cells.17 CD40 and its
binding to the CD40 ligand is an important step
in the antigen-presenting process. Our results
established that CD40 (Fig. 5) is neither expressed
on apoptotic cells nor on the living population
after culture or as fresh cells. In an earlier study15
it was shown that eosinophils from atopic patients
express CD40 to an extent of approximately 40%.
This discrepancy in results may be due to metho-
dological disparities or differences in the selection
of individuals.
The interpretation of the increased CD25 and
CD28 expression on apoptotic eosinophils from
patients compared with healthy individuals would
be that the number of receptors per cell is doubled.
This reasoning suggests that eosinophils from the
allergic patients during the pollen season are more
responsive to the mechanism, probably cytokine,
inducing the expression of CD25 and CD28. The fact
that the proportion of apoptotic eosinophils and
the relative amount of cells expressing CD25 and
CD28, as well as CD122 and CD86, are related
indicates that the same mechanism is operative
both in case of induction of apoptosis and in the
expression of new receptor types.
A common conception is that eosinophil apopto-
sis is delayed in tissues affected by allergic
inflammation.23,30,31 The delayed apoptosis is sug-
gested to be caused by the local production of
survival-enhancing cytokines, mainly GM-CSF and
IL-5. The variation in the inborn apoptotic rate of
eosinophils not affected by any cytokines has been
investigated in several studies. Increased survival
of eosinophils from patients with atopic dermatitis,
inhalant allergy and asthma has been demon-
strated.32–34 Those patients have had exacerba-
tions or been challenged, but eosinophil survival
has not been measured during pollen season. In the
present study, the survival of eosinophils from
healthy persons during the birch pollen season
decreased significantly in comparison with the
survival of eosinophils out of season. The eosino-
phils from allergic patients had the same level of
survival during the birch pollen season as the
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Fig. 5 Expression of CD40 on living (closed circles) and apoptotic (open circles) eosinophils during culture, n ¼ 19:
Results are presented as median and quartile ranges. Note that the scale on the y-axis differs from the scale in
Figs. 1–4.
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eosinophils from healthy controls and hence a
significantly decreased survival compared with
eosinophils from healthy persons out of season
(Table 1). The mechanism underlying this decrease
was not connected to the allergic reaction or the
formation of IgE antibodies to birch pollen because
the decrease is also seen in healthy persons. The
diminished viability might be a consequence of the
interaction between pollen and epithelial cells,
resulting in cytokine production from the epithelial
cells, a process that affects the survival of the
eosinophils. The only cytokine known today to
decrease eosinophil survival is TGFb; and under
some circumstances TNFa:35,36 An alternative me-
chanism could be that the inhalation of pollen by an
unknown secondary mechanism induces a reduction
of the autocrine production of IL-5 and GM-CSF
from the eosinophils in culture. Considering both
possibilities it should be kept in mind that the birch
pollen counts during the pollen seasons in question
were very high which might have had previously
undetected consequences. Analysis of the auto-
crine production from cultured eosinophils of
cytokines affecting their survival would be the task
of further research.
Our results suggest that apoptotic eosinophils
acquire a unique cell surface receptor expression
during apoptosis. The up-regulated receptors might
be involved in the signalling to other cell types and
are possibly involved in the recognition and uptake
of apoptotic eosinophils. The expression of T- and
B-cell markers could indicate that the apoptotic
eosinophils in this way are recognised as ‘‘self’’ and
therefore they avoid the occurrence of inflamma-
tion. The apoptotic process has recently been
reported not only to be non-inflammatory but also
actively anti-inflammatory through its suppression
of the pro-inflammatory systems.24 The self-recog-
nition of the apoptotic cells might be a means to
initiate the anti-inflammatory response. The up-
regulation of these markers indicates communica-
tion with T- or B-cells by mimicking the T- or B-cell
surface receptor expression. They do not seem to
be intended to be ‘‘eat-me’’ signals such as the
exposure of phosphatidylserine in that lymphocytes
do not have the ability to phagocytise other cells.
Apoptotic cells have hitherto not been recog-
nised as having any functional capacities. Concern-
ing the present results, the obvious question is
whether the binding to the IL-2 receptor a- and b-
chains or CD28 and CD86 induces any signalling in
the eosinophils or whether just the expression of
this combination of receptors could provoke any
response in the surrounding cells. Recent investiga-
tions suggest that the expression of the co-
stimulatory molecules CD28 and CD86 (B7-2) on
T- and B-cells, respectively, is preferentially con-
nected to the Th2 response.13,14,37 The expression
of CD28 and CD86 on apoptotic eosinophils might
therefore be linked to the well-known Th2 response
of T-cells in allergy. On the other hand, the
expression of CD25 is the characteristic of the
subset of T-cells known as regulatory T-cells that
are involved in the mechanism underlying tolerance
to allergen;28,29 these regulatory T-cells release
TGFb and IL-10 and suppress the formation of Th1
and Th2-cells.
We hypothesise that the apoptotic eosinophil, by
means of the expression of IL-2 receptor a- and b-
chains and the co-stimulatory molecules CD28 and
CD86, is intimately involved in the regulation of
inflammatory responses in the tissue.
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